This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Fibrillex for amyloidosis – secondary

< Back

Fibrillex for amyloidosis – secondary



January 2006

Fibrillex (NC-503, Eprodisate disodium, sodium1,3-propanedisulfonate, 1,3-propane- disulphonic acid, 1,3-PDS), an orally active amyloid precursor protein antagonist that inhibits amyloid deposition, is in development as a new treatment for amyloid A amyloidosis in patients with underlying chronic inflammation and infection. A pivotal phase II/III randomised, placebo-controlled trial in 183 patients reported that 13.4% more of the treated group had stable or improved kidney function as compared to the placebo group (although this did not meet the primary endpoint). Secondary outcomes indicated that the progression of renal disease is delayed (5-month delay to dialysis). A three-year open-label extension to the trial is ongoing.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts